Literature DB >> 8674237

CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis.

R Gerli1, C Muscat, A Bertotto, O Bistoni, E Agea, R Tognellini, G Fiorucci, M Cesarotti, S Bombardieri.   

Abstract

T cell surface expression and the functional role of CD26 antigen (Ag), a surface ectoenzyme involved in T cell activation and migration across the extracellular matrix, were analyzed in the peripheral blood (PB) and synovial fluid (SF) from patients with inflammatory arthritides. CD26 membrane expression on T cells was detected by cytofluorometry using two different monoclonal antibodies, anti-Ta1 and anti-1F7, while cell proliferation and both IL-2 and IFN-gamma production were evaluated in anti-CD3- or anti-CD2-stimulated cell cultures after Ag surface modulation with anti-1F7. The results showed that Ta1 and 1F7 Ag expression were increased on T cells from PB of patients with active, but not inactive, rheumatoid arthritis (RA). Most SF T cells from RA or other inflammatory arthritides displayed the memory marker CD45R0 and the Ta1 Ag, but lacked the 1F7 molecule. In addition, in vitro 1F7 modulation, which enhanced RA PB T cell proliferation and both IL-2 and IFN-gamma synthesis, did not synergize with anti-CD3 or anti-CD2 in inducing IL-2-dependent activation of SF T cells, but reduced IFN-gamma production. A spontaneous reappearance of 1F7 Ag on the SF T cell surface was seen after 2-5 days in culture. Phorbol myristate acetate, able to accelerate its reexpression, also restored a normal response of SF T cells to anti-1F7 comitogenic effects. These data confirm a role of the CD26 surface molecule in regulating T cell activation and lymphokine synthesis. This observation may have important implications in the regulation of T cell activity at the joint level during chronic inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674237     DOI: 10.1006/clin.1996.0091

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  14 in total

1.  Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.

Authors:  J Wahlström; M Berlin; C M Sköld; H Wigzell; A Eklund; J Grunewald
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

2.  CD26 T cells in the pathogenesis of asthma.

Authors:  K Ohnuma; T Yamochi; O Hosono; C Morimoto
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

3.  Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.

Authors:  Khalaf Kridin; Kyle Amber; Mogher Khamaisi; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

4.  Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.

Authors:  Nathalie Busso; Nicolai Wagtmann; Christian Herling; Veronique Chobaz-Péclat; Angelika Bischof-Delaloye; Alexander So; Eric Grouzmann
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

5.  CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.

Authors:  Kei Ohnuma; Tadanori Yamochi; Masahiko Uchiyama; Kunika Nishibashi; Satoshi Iwata; Osamu Hosono; Hiroshi Kawasaki; Hirotoshi Tanaka; Nam H Dang; Chikao Morimoto
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

Review 6.  T-cell activation via CD26 and caveolin-1 in rheumatoid synovium.

Authors:  Kei Ohnuma; Hiroshi Inoue; Masahiko Uchiyama; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

7.  Lymphatic-specific expression of dipeptidyl peptidase IV and its dual role in lymphatic endothelial function.

Authors:  Jay W Shin; Giorgia Jurisic; Michael Detmar
Journal:  Exp Cell Res       Date:  2008-08-03       Impact factor: 3.905

8.  Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.

Authors:  Seoyoung C Kim; Sebastian Schneeweiss; Robert J Glynn; Michael Doherty; Allison B Goldfine; Daniel H Solomon
Journal:  Ann Rheum Dis       Date:  2014-06-11       Impact factor: 19.103

Review 9.  Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?

Authors:  Aleksi Sedo; Jonathan S Duke-Cohan; Eva Balaziova; Liliana R Sedova
Journal:  Arthritis Res Ther       Date:  2005-10-26       Impact factor: 5.156

Review 10.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.